Activated macrophages (aMO) destroy more effectively cancer cells than normal cells. The mechanism by which macrophages destroy cancer cells is not known. We report here that tumor cells susceptible to aMO were killed by recombinant (r) tumor necrosis factor type a (TNF-a), whereas variant tumor cells resistant to aM4 after selection in vitro or in vivo were resistant to killing by rTNF-a. The converse selection for rTNF-a-resistant variants resulted in cells that were also resistant to killing by aM4. The sensitivity of macrophage-resistant variants was not changed to other tumoricidal cells or soluble mediators, except that the macrophage-resistant variants were also resistant to the effects of another cytotoxic protein, B-cell lymphotoxin, which is structurally related to rTNF-a. Similar results were obtained regardless of whether short-term or long-term cytotoxic effects of aM4 were measured. Finally, it was shown that killing of tumor cells by murine aMO was completely inhibited with a polyclonal antibody that neutralizes the effects of murine TNF-a. These results suggest a major role for TNF-a in tumor cell destruction by aM4 in vitro and in vivo.
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Macrophages (MO) can be activated in vitro to exhibit cytolytic activity against malignant but not normal cells (1-6). Although the mechanism by which this occurs is not known (7) , it appears to involve both cell contact and the secretion of a number of distinct cytotoxic substances (8) (9) (10) (11) (12) .
Tumor variants resistant to activated macrophages (aMO) (13) can be used to explore the mechanism by which these effector cells induce target cell destruction. Such variants have been isolated from murine ultraviolet-light-induced tumors, which are highly immunogenic regressor tumors (14) sensitive to aM4 in vitro (13) . Host (13) .
We show here that aM4-resistant variants have acquired selective resistance to tumor necrosis factor type a (TNF-a), a cytotoxic molecule produced by aM4 (9, 15, 16 
RESULTS
Analysis of the MO-resistant variants in Fig. 1 (a-d Fig. 2b shows that the variants and the parental tumor were equally resistant to murine rIL-1. There is substantial evidence demonstrating that aMO produce reactive oxygen intermediates, such as hydrogen peroxide (11) , that play an important role in MO antimicrobial activity (23) . However, the variants demonstrated wild-type (parental) sensitivity to hydrogen peroxidemediated lysis (Fig. 2c) . It has also been reported that arginase released from aM4 can be tumoricidal by depleting arginine from the medium (10) . Thus, the MO-resistant variants may have acquired decreased arginine dependence.
However, the addition of excess arginine (500 ,ug/ml) to the culture medium did not affect the sensitivity of the parental as compared to the variant tumor cells (data not shown).
Finally, the sensitivity of the MO-resistant variants to rTNFa (9, 15, 16) was tested. The data shown in Fig. 2d demonstrate that MO-resistant variants were also completely resistant to the cytotoxic effects of human rTNF-a. Furthermore, the effects of human rTNF-a on UV1591-RE were completeAbbreviations: MO, macrophage(s); TNF-a, tumor necrosis factor type a; TNF-p8, B-cell lymphotoxin; IL-1, interleukin 1; a, activated; r, recombinant; NK, natural killer.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 6 hr with lipopolysaccharide and lymphokine, and used as effectors in a 16-hr 51Cr release assay (a and e). The activation requirements and phenotypic characterization of these aM4 were described in detail (13) ; 10T½ fibroblasts were used as negative controls. Susceptibility to osmotic lysis (b and f) was determined for 51Cr-labeled target cells in a 4.5-hr assay using complete medium diluted with distilled water to the osmolarity indicated. Maximum release (100%) was determined by saponin lysis (13) . NK cells were derived from spleens of poly(I).poly(C)-injected C3H mice and were used in a 4.5-hr 51Cr release assay (20) . These NK cells lysed YAC-1 target cells 81, 76, 70, 52, and 33% at the effector:target ratios shown (c and g). NK cells were eliminated in the control with an anti-GM1 antibody and complement. Uninduced spleen cells caused less than 5% lysis of the UV1591-RE tumors. Cytolytic T cells were UV1591-RE tumor-specific cytolytic T-cell clones (21) directed against the A antigen specific for the parental 1591 regressor tumor (d) or the B antigen [a second independent UV1591-specific antigen retained by host-selected progressor tumor variants (20) , (h)] using the independently derived UV-induced C3H tumor 2240-RE as negative control. The SEM for each point indicated was always --10% of the value of each point shown. The data represent pooled values from three separate experiments.
ly neutralized by preincubation with a monoclonal antibody directed against human rTNF-a (Fig. 2d, negative control) .
We have shown that tumors that have escaped immune defenses of the normal host show progressive growth, have lost certain tumor-specific antigens (24) , and also demonstrate increased resistance to aM4 (13) . Figs. 1 (Lower) and 2 (Lower) show the analysis of such host-selected variants and show that these variants have also acquired a selective resistance to human rTNF-a (Fig. 2h) while remaining sensitive to killing by other mechanisms (Figs. 1 f-h and 2 f  and g ).
Human TNF-,p is a cytotoxic protein whose sequence is about 30% homologous to human TNF-a (25) . Fig. 3 shows that both human rTNF-a and human rTNF-/3 had equivalent cytotoxic effects on the parental UV1591-RE tumor, while the MO-resistant variant showed similar resistance to both recombinant proteins. This result raises the possibility that TNF-a and TNF-p8 employ common effector pathways, a suggestion supported by other data that show that human rTNF-a and human rTNF-p compete for binding the same cellular receptor (26) . Furthermore, TNF-a may also have similarity to T cell-derived lymphotoxin since others have shown that an antiserum to purified T-cell lymphotoxin could block macrophage-mediated cytotoxicity (30) .
To confirm the linkage between resistance to human rTNF-a and resistance to aM4, two human rTNF-a-resistant UV1591 cell lines were selected and tested for resistance to aM4. Similar to MO-resistant variants, the human rTNF-aresistant variants (Fig. 4 a and c) were stable after 25 generations without selection in vitro or one in vivo passage in nude mice. More importantly, these human rTNF-aresistant variants were substantially more resistant to aM4 (Fig. 4 b and d) . Similar results were obtained whether we measured the release of 51Cr from injured tumor cells in a 16-hr short-term assay (Fig. 4b) or the uptake of 51Cr by surviving tumor cells in a 72-hr long-term assay (Fig. 4d) . Furthermore, in variants selected for resistance to either agent, the correlation between resistance to rTNF-a or aM4 was confirmed using the independently induced tumor UV1316-RE and its aM4-resistant or TNF-a-resistant variants (data not shown). There was, however, a residual sensitivity of the human rTNF-a selected UV1591-RE variants to aMO (Fig. 4 b and d (19) . For measuring sensitivity to enzyme-generated hydrogen peroxide (c and g), target cells were exposed to various concentrations ofglucose oxidase for 4 hr as described (11 incomplete resistance to the cytotoxic effects of aMOsecreting murine TNF-a. This could be due to the fact that human rather than murine rTNF-a had been used for the selection. Fig. 5a indicates that variants selected for resistance to murine rTNF-a (18) were completely resistant to cytolysis by murine aM4 and these variants, therefore, resembled more closely the variants selected with murine aMk.
Evidence that suggests directly that the observed cytotoxic effects of aMo and TNF-a follow identical pathways is shown in Fig. 5b (Fig. 4 a and c) . The pooled values of two separate 16-hr 51Cr release assays are shown. (b) Neutralization of tumor cell killing by aMO using antibodies raised against murine rTNF-a. The pooled results of two experiments using a modified 51Cr release assay are shown. aM4 were preincubated for 16 hr with either media alone, preimmune serum, or the indicated amounts of a rabbit polyclonal antibody that neutralizes the cytotoxic effects ofmurine rTNF-a. The amount of preimmune serum added was 16 ul, equal to the largest volume of neutralizing antiserum added. Labeled parental 1591-RE target cells were added without further washing, and the amount of51Cr released into the supernatant was determined after 16 hr. The data represent pooled values from two separate experiments.
